Navigation Links
Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
Date:1/3/2008

DANBURY, Conn., Jan. 3 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that the Company has completed enrollment of its two pivotal Phase III clinical trials of VIAject(TM), a rapid-acting injectable meal-time insulin for use by patients with Type 1 and Type 2 diabetes. The Company also announced its intention to build and operate a fill and finish manufacturing facility for VIAject(TM), on the campus of its current headquarters in Danbury, Connecticut.

"We are pleased to have completed enrollment of the VIAject(TM) clinical trials on schedule," commented Solomon S. Steiner, Ph.D., Chairman and Chief Executive Officer of Biodel. "We believe that VIAject(TM)'s superior pharmacokinetic and pharmacodynamic profile should improve the treatment of millions of patients with diabetes."

Biodel has now enrolled over 400 patients with Type 1 diabetes at approximately 60 clinical sites in the United States, Europe, and Asia, and over 400 patients with Type 2 diabetes at approximately 50 clinical sites in the United States, Europe, and Asia. Both studies are multi-center, open label and six months in duration, comparing the effects of VIAject(TM) to Humulin(R) R, the leading recombinant human insulin. Biodel expects to complete these trials and, if the trials are successful, the Company intends to submit a New Drug Application for VIAject(TM) to the Food and Drug Administration by the end of 2008.

To prepare for commercialization of VIAject(TM), the Company plans to build a fill and finish manufacturing facility which will be dedicated to manufacturing a full line of VIAject(TM) liquid formulations and presentations. The dedicated manufacturing facility will improve margins, provide superior quality control, and better inventory control. Biodel anticipates that the facility will cost under $15 million and will be available for commercial production in 2009.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceuti
'/>"/>

SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
3. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
4. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
5. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
6. Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
7. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
8. U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCs DVC and Baxter
9. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
10. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
11. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)...and, January 7 Circassia Ltd, a sp...rgy and critical care, today,announced that follo...with,its ToleroMune(R) anti-allergy technology, t...for a further phase II clinical trial in cat aller...ecruited 120 patients with confirmed,cat allergie...
(Date:1/6/2009)... The Michael J. Fox Fou...our industry research teams for pre-clinical resea...sease. , , The funding was awarded under the Fo...This program, first launched in 2006, supports and...research. TDI is part of MJFF,s focus on ,de-r...
(Date:1/6/2009)...e, January 6 , - ...boration Until,December 2011 , - Expansion...body,Discovery in Ophthalmology , - Revise...rgan,Sublicenses to a Third Party , Exon...d a reinforcement,of its existing drug discovery ...
(Date:1/3/2009)... , , ROSEMONT, Ill., Jan. 2 /PRNewswire-USN...growing technology providing an increasing number ...f back pain according to an article in the January... of Orthopaedic Surgeons ( http://www.jaaos.org/ )...s, additional technical developments will allow MR...
Breaking Medicine Technology:Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 3Roche completes acquisition of ARIUS 7890 1Roche completes acquisition of ARIUS 7890 2Connecticut State Medical Society and Genomas Co Sponsor Forum on DNA Guided Medicine and the Path to Personalized Health Care 7888 1Connecticut State Medical Society and Genomas Co Sponsor Forum on DNA Guided Medicine and the Path to Personalized Health Care 7888 2Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 1Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 2Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 3Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 4World Alzheimer 26apos 3Bs Day 2008 Special Report 3A New Alzheimer Targets Take Center Stage 26688 1World Alzheimer 26apos 3Bs Day 2008 Special Report 3A New Alzheimer Targets Take Center Stage 26688 2
... - Journal Article Also Demonstrates the Promise o...ibiotics -, PALO ALTO, Calif., June 21, 2007 /PRNe...d pharmaceutical company, announced,today that the...that details how AN2690, the company,s lead clinic...th synthesis of a specific,protein required for fu...
... FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - N...ublication in the June 23 issue,of the journal The...ne therapy trial for Parkinson,s disease and the f...,s own brain cells for any adult,neurodegenerative... in 12 patients with,advanced Parkinson,s disease ...
Other Medicine Technology:Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug,AN2690; Findings Published in Science 2Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug,AN2690; Findings Published in Science 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 4Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 5Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 6
(Date:1/8/2009)...ewswire/ -- Today, the National Hospice and Pallia... leadership organizations issued a consensus state...protection of the Medicare Hospice Benefit. The or...ied message about end-of-life care are the America...Hospice and Palliative Nurses Association, Nationa...
(Date:1/8/2009)... January 9 , , WASHINGTON, Jan. 8 /PRNewswire-...onal Union (SEIU) President Andy Stern convened a ...e Board to discuss the forced transfer of 65,000 n...d Healthcare Workers-West (UHW), its third largest...omorrow. , , According to reports, several exec...
(Date:1/8/2009)... at his confirmation hearing to be the next Secret...GTON, Jan. 8 Bipartisan... Tom Daschle, nominee for Department of Health and...w BPC founder and friend Senator Bob Dole at his c...d by the Senate Health, Education, Labor, and Pens...
(Date:1/8/2009)...ts, study suggests , , THURSDAY, Jan. 8...strongly they would react to racist acts, a new Ca...udy participants at York University, in Toronto, s...te person rather than a black one, even after thei...person when he left the room. , "And the raci...
Breaking Medicine News(10 mins):Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 3Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 4Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 5Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 6Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 7Health News:SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:Many Turn Blind Eye to Racism 2
...to the conference held at Varca in Goa it is found...rom high homocysteine levels. //The two day confe...und that extreme vegetarian practices lead to hype...ituation by increasing the risk of developing dise...
...onship between obesity in childhood and extent of ...ording to a recent study based on Scottish childre...derlying connection between the extent of physical...e finding hovered around the importance of genetic...
...Kashmir health department today advised people to ...ood of increase in water-borne diseases like diarr...ve been asked to boil drinking water for at least ...getables and fruit thoroughly before eating, an of...
...udies published in the Mayo Clinic Proceedings rev...awal and cocaine use with the onset of cardiac syn...cterized by chest pain, shortness of breath mimics...hed light on ‘broken heart syndrome,’ a still some...
Other Medicine News:Health News:Sudden Opioid Withdrawal Results in ‘Broken Heart Syndrome 2
...nHeart Left Ventricular Assist System (LVAS), manu... to be used as a destination therapy for patients ...V) congestive heart failure, for which heart trans...VAS is not intended as a bridge to transplant or a...
...VAD System includes three major components: Blood ...ortable Driver. This system provides partial or to... with conventional therapy, is unable to maintain ...ccomplish support, blood flows from the natural he...
Datascope presents a unique new product for post-hemostasis puncture site management. Safeguard is the first product ever to combine a built-in inflatable bulb and a sterile dressing- providing adjus
... catheter is inserted into the subclavian or jugul...e Cool Line incorporates two proprietary, MocroThe...lled saline flowing within a closed-loop design, e...ulation. The Cool Line combines two important pat...
Medicine Products: